|
CC-1088 is a thalidomide analogue inhibitor of phosphodiesterase 4 that was being developed up to 2005 by Calgene Corp., for treating of inflammatory diseases and myelodysplastic syndromes. CC-10004 was found to be a preferable. ==See also== 抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「CC-1088」の詳細全文を読む スポンサード リンク
|